As GLP-1 receptor agonist drugs like Ozempic®, Wegovy®, and Mounjaro® continue to dominate conversations around weight management and metabolic health, supplement companies are increasingly exploring ingredients that may support the body’s natural GLP-1 response.
This has created a rapidly growing category of products often marketed as “GLP-1 inspired supplements.”
Unlike prescription GLP-1 drugs, these products do not contain synthetic GLP-1 agonists. Instead, they typically use dietary ingredients, botanical extracts, fibers, probiotics, proteins, or other functional ingredients that may influence satiety, digestive signaling, or gut hormone activity.
At dicentra, we are seeing significant interest in this category across foods, beverages, dietary supplements, and natural health products — particularly among companies looking to innovate responsibly while navigating increasingly complex regulatory expectations.
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone released by intestinal endocrine cells in response to food intake. It plays a role in:
Prescription GLP-1 agonist drugs are designed to mimic or enhance these physiological effects through synthetic pharmaceutical compounds.
GLP-1 inspired supplements, however, generally focus on ingredients that may indirectly support natural GLP-1 activity or related metabolic pathways rather than directly acting as GLP-1 receptor agonists.
The rapid growth of prescription GLP-1 drugs has created broader consumer interest in:
As a result, many companies are exploring functional ingredients researched for potential GLP-1 activity or related physiological effects.
Examples of ingredients discussed in the scientific literature include:
Importantly, the existence of preliminary research does not automatically mean these ingredients are clinically substantiated for weight loss or obesity-related claims.
At dicentra, one of the most common regulatory misconceptions we encounter is the assumption that demonstrating a biomarker effect — such as increased GLP-1 levels — automatically supports broad appetite or weight management claims. In reality, regulatory substantiation standards are much more nuanced.
One of the most important regulatory distinctions in this category is the difference between:
In the United States, selling GLP-1 analogs as dietary supplements would generally violate FDA’s drug preclusion provisions under the FD&C Act, since GLP-1 analogs were first marketed as drugs, rather than food ingredients.
Similar restrictions also apply in:
This means companies developing supplements in this space should focus on ingredients that may indirectly influence satiety, digestive signaling, or gut hormone pathways rather than attempting to replicate prescription GLP-1 drugs themselves.
Many GLP-1 inspired supplements rely on ingredients that already have a history of use in foods or dietary supplements.
However, regulatory status is still highly ingredient-specific and may depend on:
For food ingredients in the United States, companies may need to evaluate whether an ingredient is:
For dietary supplements, companies may also need to evaluate New Dietary Ingredient (NDI) requirements depending on the ingredient and marketing history.
At dicentra, we often advise companies that even ingredients with established regulatory histories may require additional safety evaluations when:
Many GLP-1 inspired dietary supplements combine multiple active ingredients intended to support metabolic health or satiety pathways simultaneously.
For example:
Claims are one of the most important regulatory risk areas in the GLP-1 supplement category.
In both Canada and the United States, companies cannot market foods or supplements as treatments, cures, or preventive products for obesity or diabetes.
Examples of problematic claims may include:
Instead, companies typically focus on structure/function or functional-style claims supported by appropriate scientific substantiation.
Potentially more appropriate claim styles may include:
At dicentra, we frequently advise companies that claims substantiation should involve more than biomarker changes alone. Human studies evaluating satiety, appetite, or metabolic endpoints are often critical to supporting defensible product positioning.
One of the most important scientific considerations in this category is that increases in GLP-1 biomarkers do not always translate into meaningful satiety or weight management outcomes.
dicentra’s webinar highlighted several examples where ingredients demonstrated changes in GLP-1 measurements without corresponding effects on appetite or body composition outcomes.
This is why study design becomes especially important for:
Clinical substantiation strategies often require both:
As the GLP-1 inspired supplement category grows, regulators, retailers, and consumers are placing greater scrutiny on:
Companies entering this category increasingly need:
At dicentra, we are seeing growing demand for clinical and regulatory support in this space as companies work to differentiate legitimate science-backed products from aggressive or misleading marketing approaches.
dicentra supports companies developing GLP-1 inspired supplements, functional foods, and metabolic health ingredients across the U.S., Canada, and Europe.
Our services include
Whether your company is developing a satiety-support ingredient, metabolic wellness supplement, probiotic formulation, or GLP-1 inspired product concept, dicentra can help assess the regulatory and scientific considerations associated with commercialization.
If your company is evaluating GLP-1 inspired supplement ingredients or metabolic health product claims, reach out to dicentra to discuss your regulatory strategy, scientific substantiation, and commercialization pathway.
Talk to our team about your GLP-1 Supplement GRAS strategy →